ContextInhaled long-acting β2-agonists improve asthma control when added to inhaled
corticosteroid (ICS) therapy. ObjectiveTo determine whether ICS therapy can be reduced or …

ContextLong-acting β2-agonists are prescribed for patients with persistent asthma and are
sometimes used without inhaled corticosteroids (ICSs). No evidence exists, however, to …

This randomized, double-blind, parallel, multi-center study was designed to determine
whether the addition of salmeterol to existing inhaled corticosteroid therapy provides greater …

BACKGROUND: The current stepwise approach to pharmacotherapy in the treatment of
asthma includes the initiation of an inhaled corticosteroid with the addition of a long-acting …

BACKGROUND: Current treatment guidelines define inhaled corticosteroids such as
fluticasone propionate (FP) as the cornerstone of anti-inflammatory therapy for asthma …

Background Treatment guidelines recommend the use of inhaled corticosteroids in patients
with asthma who have persistent symptoms and the “stepping down” of therapy to the …

Background: Recent analyses have suggested an increased risk for serious asthma-related
adverse events in patients receiving long-acting β-agonists. Purpose: To examine whether …

Background Although guidelines recommend daily therapy for patients with mild persistent
asthma, prescription patterns suggest that most such patients use these so-called controller …

Background: Traditional clinical outcomes have demonstrated that salmeterol improves
pulmonary function and reduces asthma symptoms. However, they do not evaluate how …

Background Despite oral corticosteroid therapy, some patients with asthma have frequent
exacerbations requiring emergency room visits, hospitalization, and occasionally …